◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › CDXS

Codexis, Inc. (CDXS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-16

Codexis, Inc. (CDXS) operates in the Biotechnology industry and is headquartered in Redwood City, United States with about 146 employees. Its market capitalization is roughly $201 million. In the fiscal year ended 2025-12-31, CDXS reported $70M in revenue and ($44M) in net income.

Codexis, Inc.

Interactive charts & full statements → Open the CDXS valuation workbench →

CDXS Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$70M$59M$70M$139M
Gross Profit$61M$43M$57M$101M
Operating Income (EBIT)($38M)($58M)($55M)($32M)
Net Income($44M)($65M)($76M)($34M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CDXS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$15M$39M$9M$15M$8M
Gross Profit$13M$37M$6M$13M$5M
Operating Income (EBIT)($8M)$14M($19M)($13M)($20M)
Net Income($9M)$10M($20M)($13M)($21M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CDXS Free Cash Flow History

CDXS Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$148M$149M$137M$250M
Total Liabilities$97M$82M$50M$106M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CDXS viewer.

Other Companies in Biotechnology

← CDWAll stocksCDZI →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.